ANNOUNCEMENT
Montreal, November 22, 2024 – CQDM is proud to announce that the collaborative R&D project, which developed an AI-powered multimodal prognostic platform to predict disease progression, has won the Industrial Research Sectoral Groups (RSRI) Innovation Award at the 34th ADRIQ Gala held last night at the Palais des congrès de Montréal.
This collaborative R&D project was made possible through the joint financial support of Perceiv AI, DalCor Pharmaceuticals Canada, and the Quebec Government, provided through CQDM. It enabled the design and testing of a groundbreaking predictive tool: Perceiv AI’s Foresight platform. By analyzing multimodal retrospective data (including clinical imaging and molecular and genetic information) from patient cohorts at the Montreal Heart Institute (MHI) who had experienced a cardiovascular event, Perceiv AI successfully predicted the risk of a second cardiovascular event in these patients with significantly higher accuracy than tools currently available on the market.
Through this collaboration, Perceiv AI demonstrated proof of concept for its Foresight platform in predicting cardiovascular event risks while reducing required sample sizes by nearly half (42%) without compromising statistical power. This advancement is revolutionary, mitigating risks associated with clinical trials and facilitating the development of new drugs. This success paves the way for the platform’s application to other medical indications, addressing urgent industry needs and enabling Perceiv AI to diversify its offerings.
Link to initial project announcement, click here.
“CQDM congratulates Perceiv AI, DalCor Pharmaceuticals, and Drs. Jean-Claude Tardif and Marie-Pierre Dubé for this well-deserved recognition. I want to highlight the exceptional work of the project partners, whose collaboration made it possible to achieve proof of concept for Perceiv AI’s platform, designed to stratify and predict at-risk subpopulations for certain pathologies. This achievement perfectly illustrates the power of collective effort in pushing the boundaries of healthcare innovation, ” said Diane Gosselin, President and CEO of CQDM.
“This award reflects the strength of collaboration between scientific, industrial, and institutional partners in addressing major health challenges. This project represents not only a technological breakthrough but also a collective commitment to transforming clinical trials and improving patient outcomes. We are honored by this recognition, which underscores Perceiv AI’s ongoing efforts to innovate in precision medicine”, stated Dr. Christian Dansereau, President and CEO of Perceiv AI.
“We are thrilled with the success of this collaboration, which has harnessed artificial intelligence to more accurately identify patients at risk of experiencing a second cardiovascular event. This achievement significantly enhances clinical studies and improves patient care,” stated Dr. Fouzia Laghrissi-Thode, President and CEO of Dalcor Pharmaceuticals.
“We are proud that our precision medicine initiative and our expertise in clinical studies contributed to this success alongside Perceiv AI in artificial intelligence”, said Dr. Jean-Claude Tardif, Director of the Montreal Heart Institute Research Center, Professor of Medicine at the University of Montreal, and Canada Research Chair in Personalized Medicine.
-30 –
About the ADRIQ RSRI Award
Created in 2019, this prize presented by the nine (9) RSRIs (CQDM, CQRDA, CRIAQ, CRIBIQ, CRITM, InnovÉÉ, MEDTEQ, Prima and Prompt) highlights the strength of the links between the research community and the industry and highlights the significant impact of a collaborative research project on the Quebec economy.
About CQDM
Facilitator of biopharma innovation
CQDM is a not-for-profit biopharmaceutical research consortium whose mission is to support and facilitate multi-stakeholder collaborative R&D aimed at accelerating the translation of innovative technologies by the biopharma industry into solutions that address unmet medical needs, while generating significant benefits for the Quebec and Canadian economy. For more information, please visit the website: www.cqdm.org and join us on Twitter/X @CQDM_Canada and LinkedIn.
About DalCor Pharmaceuticals
DalCor is a biopharmaceutical company with a focus on addressing cardiovascular disease, the greatest global healthcare burden. Our purpose is to deliver the first pharmacogenomic precision medicine in cardiovascular disease that specifically targets patients with the ADCY9 AA genotype. The company has operations in Canada, the UK, Switzerland, and the U.S. For more information, please visit www.dalcorpharma.com
About Perceiv AI
Perceiv AI is a precision medicine technology company developing digital biomarkers to help clinical trials succeed by pairing multimodal biomedical data and proprietary artificial intelligence technology to target the most suitable patients. Our AI-driven turn-key solutions can be used for prognostic enrichment and for precise targeting of responders to therapeutic interventions. Founded in 2018, Perceiv AI has partnerships with small and large biopharma companies in Canada, the United States, and Europe. For more information, please visit www.perceiv.ai, Twitter, and LinkedIn
Media Contact:
Julia Serafino
Marketing & Communications Manager
CQDM
438-543-9498
[email protected]
